National Association of State Controlled Substances Authorities

NASCSA NEWS

April 24, 2013

Contact Us

NASCSA
72 Brook Street
Quincy, MA 02170
Phone: (617) 472-0520
Fax: (617)472-0521
E-mail: kathykeough@nascsa.org
Website: www.nascsa.org
Webmaster: wward@nascsa.org

Did You Know NASCSA is on Twitter?

If you have a Twitter account, please make sure to follow us @NASCSA. Our followers are growing by leaps and bounds so spread the word and stay connected!

Long-Time Member Danna Droz Takes on New Role

Danna Droz, RPh., JD, formerly Director of Ohio's Prescription Drug Monitoring Program, and a leading expert on PDMPs has accepted a new role with the National Association of Boards of Pharmacy as Prescription Monitoring Program Liaison.

Danna, who has received numerous national awards including NASCSA's Annual Presdent's Award, has served as an officer with NASCSA and recently was

Presidents Message

Each year the member states of NASCSA elect officers and members of the Executive Board, who along with our Executive Director work tirelessly to improve the organization and to provide as many services as possible given the fiscal confines of the organization. As a mostly volunteer organization, the board relies heavily on the expertise and input from the active participation of its members and associate members.

This year is no different, with a number of very active committees who are hard at work behind the scenes working on your behalf. Among the committees that are meeting on a regular basis include the following: Program; Special Projects; Survey/Data; Resolutions/Bylaws and Membership. We will be reporting more extensively on accomplishments and plans of the committees as well as several initiatives underway. In the meantime, after extensive discussion, a decision has been made to hold the annual conference from 1 p.m. on Tues, Oct.22 through Fri., Oct. 25, 2013 in Kansas City, Missouri. In the meantime, if you have suggestions on what the organization could be doing on your behalf please feel free to contact me.

Finally, I would like to take this opportunity to welcome our latest Platinum sponsor, GW Pharmaceuticals.

Sincerely,

Mark Keeley, President

elected chair of the Executive Committee to fill a vacant seat. She will continue to fill that role until the annual conference this fall.

DEA to Hold Prescription Drug Take-Back Day

The US Drug Enforcement Administration (DEA) will hold its sixth National Prescription Drug Take-Back Day, Saturday, April 27, 2013 from 10 a.m. to 2 a.m. during which consumers may safely dispose of unwanted medications at one of thousands of collection sites coordinated by DEA and provided by law enforcement agencies and community organizations in all 50 states and United States jurisdictions. The DEA online collection site locator is available here. The take-back service is free and anonymous, with no questions asked. Sites will accept tablets, capsules, and all other solid dosage forms of unwanted medication. Personal information may be blacked out on prescription bottles, or medications may be emptied from the bottles into the bins provided at the events. A total of over 2 million pounds of unwanted medication were collected for safe and secure disposal during the previous five take-back days combined.

Pictured are members of NASCSA's Executive Committee at their recent meeting year meeting that took place in Boston, MA April 6-7, 2013.

NASCSA's Executive Committee Meets at Midyear Meetng

While NASCSA's Executive Committee holds frequent conference calls throughout the year to continue the work of the organization, over the past several years, the group has held a midyear meeting in order to have continued focused discussions in-person. Among the items discussed during the meeting included the following:

- Nominations for honorary memberships;
- Discussion of proposed bylaws changes as proposed by the Bylaws/Resolutions Committee;
- Brainstorming session on potential resolutions for consideration;
- Detailed review of NASCSA's finances and recommendations for investments;
- Revisions to written policies of the Executive Committee; and
- Review/discussion of NASCSA's strategic plan.

A complete recap of these and other items will be provided at the annual conference at the first business session.

Save the Date for 29th Annual NASCSA Conference

Oct. 22-25, 2013

FDA To Track Illicit Product Trade Online

The US Food and Drug Administration recently announced its intent to hire a contractor to track the illegal online trade or marketing of FDA-regulated products, including prescription drugs, dietary supplements, medical devices and tobacco, according to a procurement document posted on the agency's website. The contractor would in turn sift through the information posted to online chat rooms, social networking platforms and other websites. For more information click here.

Federal Bill Would Require Training to Prescribe Controlled Substances

U.S. Senators Jay Rockefeller and Joe Manchin along with Representative Nick Rahall, all from West Virginia reintroduced the Prescription Drug Abuse Prevention and Treatment Act, which would require training for health care professionals before they may register with the Drug Enforcement Administration (DEA) to prescribe controlled substances. The bill would also increase federal support for state prescription monitoring programs.

Has Your Contact Information Changed?

If your contact information changes, please login using

Even though spring has just arrived, it's not too early to mark your calendars for the 29th Annual Conference of the National Association of State Controlled Substances Authorities (NASCSA) to take place at the Westin Crown Center in Kansas City, Missouri. **Please note that the NASCSA conference will take place October 22-25, 2013**. The hotel is located in the heart of beautiful Kansas City, within walking distance of numerous restaurants and shopping. Check NASCSA's website at www.nascsa.org for important updates on the conference. The conference program will be available this summer.

The Alliance of States with Prescription Drug Monitoring Programs will meet Oct. 21-22, 2013.

The Executive Committee has authorized the awarding of six (6) travel scholarships to attend the Annual conference. Travel scholarship criteria as well as the application form and instructions have already been posted at http://www.nascsa.org/scholarships.htm. The deadline for submitting applications is **June 28, 2013**.

NASCSA a Presence at National RX Drug Abuse Summit

Plans Underway to Exhibit at Next Month's NABP Annual Meeting

Vice President Ralph Orr attended the 2nd National RX Drug Abuse Summit in Orlando, Florida earlier this month where NASCSA was one of more than 30 exhibitors to participate at the widely attended event. NASCSA's Executive Committee identified the need to spread the word about the organization to a broader range of individuals and organizations in 2012-2013 and it was felt that this conference was a good first step. Given the number of attendees (approximately 800) and the number of individuals' interest generated from visits to the NASCSA booth, it appears NASCSA continued to spread the word about its mission.

NASCSA has made plans to exhibit at next month's annual meeting of the National Association of Boards of Pharmacy (NABP) in St. Louis, Missouri May 18-21, 2013. Ronald Klein and Margaret Clifford, both of whom are members of the executive board of NASCSA will staff the booth during the exhibit and poster session of the meeting. We encourage attendees to visit our booth and say hello!

NASCSA's Executive Committee Participates in Conference Call with the General Accounting Office

Staff from the General Accounting Office recently requested that

the original email address you originally had subscribed with and update any information including your new email address and updated contact information.

State Regulatory Developments

Did you know that NASCSA publishes a monthly compilation of state regulatory actions related to pharmacy and controlled substances. State Regulatory Developments is located on the website here.

Please Consider Volunteering

As a small nonprofit organization, NASCSA relies heavily on volunteers throughout the year and during the annual conference. There are many volunteer opportunities including assisting during the business meetings, serving on committees and serving as an officer or member of the Executive Committee. If you are interested in volunteering, please contact Kathy Keough at KathyKeough@nascsa.org or a member of the Executive Committee to learn how you can get involved.

New Drug Approved to Treat ADD/ADHD

The Food and Drug Administration (FDA) recently approved a new drug for the treatment of ADHD in patients ages 6 year and older. The drug Quillivant

members of NASCSA's Executive Committee participate in a conference call earlier this year to address the many ways in which states' regulate controlled substances that may differ from each other. Members of the board participate in the call and responded to general questions posed by GAO staff, which is expected to release a final report later this spring, focusing on drug shortages as well as other related issues. "This was a unique opportunity for NASCSA to show its expertise and provide a valuable resource to policymakers in the nation," said NASCSA's President Mark Keeley. "We were delighted by the opportunity to provide input and look forward to a long-standing working relationship with our federal partners.

Nevada Joins NABP PMP InterConnect

The Nevada Prescription Monitoring Program (PMP) to has become the latest state to join the National Association of Boards of Pharmacy (NABP) to participate in the PMP InterConnect®, a system that facilitates securing sharing of PMP data across state lines. Fourteen states - Arizona, Connecticut, Illinois, Indiana, Kansas, Kentucky, Louisiana, Michigan, New Mexico, North Dakota, Ohio, South Carolina, South Dakota, and Virginia - have now deployed NABP InterConnect. Further, eight additional states have signed Memorandums of Understanding (MOU) to participate in Interconnect. NABP continues to work with other states to facilitate their participation in the NABP InterConnect, and it is anticipated that more than 25 states will be sharing data or will have executed an MOU to participate in NABP InterConnect in 2013. The NABP InterConnect is a highly secure communications exchange platform that facilitates the transmission of PMP data across state lines to authorized requestors, while ensuring that each state's data-access rules are enforced. Additional information about NABP InterConnect is available in the Programs section of the NABP Web site.

From the States

Massachusetts - The Massachusetts Department of Public Health will hold public hearings this month on proposed regulations implementing a state ballot question to allow for the medical use of marijuana for certain conditions. The law requires that patients must have a debilitating condition to receive written authorization from their doctor to buy the drug. The conditions include cancer, HIV/AIDS, hepatitis C and amyotrophic lateral sclerosis (ALS), but patients and their doctors would have final say about other qualifying conditions. A copy of the proposed regulation and background materials is found here.

New Mexico - The New Mexico legislature enacted House Bill 146, an anti-methamphetamine bill authored by Representative Antonio "Moe" Maestas (D-16). Once Governor Susana Martinez (R-N.M.) signs the bill

XR, (methylphenidate hydrochloride) oral suspension is manufactured by Pfizer.

NASCSA Forum

Members are strongly encouraged to take advantage of the "Forum" site for members and others interested in a variety of topics related to controlled substances, prescription monitoring programs, trends, legislation and other issues. The Forum, located at http://forum.nascsa.org is also accessible from the main website www.nascsa.org. The Forum requires a one-time initial registration to create a user name and password in order to post or subscribe and is moderated by volunteers. NASCSA has initially limited the number of "forums" included, however if you would like to suggest a new forum subject please send your suggestion to KathyKeough@nascsa.org. Detailed instructions on how to use the Forum are also included on the site.

into law, New Mexico will become the 27 state to adopt electronic pseudoephedrine (PSE) sales blocking technology.

Georgia - The Legislature has passed a bill targeting "pill mills" in the state that will require all future clinics be owned by physicians licensed in the state and affects clinics where greater than 50% of patients are being treated for chronic pain. The bill is now before the Governor.

DEA Issues Proposed Rule on Synthetic Marijuana

The US Drug Enforcement Administration (DEA) recently issued a notice of intent to temporarily schedule three synthetic cannabinoids into the Controlled Substances Act (CSA) pursuant to the temporary scheduling provisions of **21 U.S.C. 811**(h). The substances are 1-pentyl-1H-indol-3-yl)(2,2,3,3- tetramethylcyclopropyl)methanone (UR-144), 1-(5-fluoro-pentyl)-1H- indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (5-fluoro-UR-144; XLR11) and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA, AKB48). This action is based on a finding by the Deputy Administrator that the placement of these synthetic cannabinoids into Schedule I of the CSA is necessary to avoid an imminent hazard to the public safety. Any final order will be published in the Federal Register and may not be issued prior to May 13, 2013. Any final order will impose the administrative, civil, and criminal sanctions and regulatory controls of Schedule I substances under the CSA on the manufacture, distribution, possession, importation, and exportation of these synthetic cannabinoids. The proposed rule is found here.

FDA Approves Abuse-Deterrent Labeling for Reformulated OxyContin

The U.S. Food and Drug Administration late last week approved updated labeling for Purdue Pharma L.P.'s reformulated OxyContin (oxycodone hydrochloride controlled-release) tablets. The new labeling indicates that the product has physical and chemical properties that are expected to make abuse via injection difficult and to reduce abuse via the intranasal route. In a prepublication version of a notice that was published in the Federal Register on April 18, 2013, FDA has determined that OXYCONTIN (oxycodone hydrochloride controlled-release) Tablets, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg, and 160 mg, approved under NDA No. 020553, have been discontinued for reasons of safety or effectiveness. The highly anticipated decision was made on the same day that U.S. Patent No. 5,508,042 was set to expire, potentially paving the way for ANDA approvals, and on the same day FDA announced the approval of abuse-deterrent labeling for a reformulated version of OXYCONTIN approved under NDA No. 022272 (presumably in accordance with FDA's draft guidance on the topic - see here). The move also comes just a day after resolutions were introduced in the U.S. Senate (S. Res. 97) and House of Representatives (H. Res. 161) expressing the sense that FDA should encourage the use of abuse-deterrent formulations of drugs. (Congress is currently considering legislation - the Stop Tampering of Prescription Pills Act of 2013 (H.R. 486) that would establish new requirements for tamper-

resistant drugs. There has been growing pressure for FDA to adopt standards requiring manufacturers and marketers of generic prescription opioids to develop tamper-resistant versions of such products including the National Association of Attorneys General as well as a number of members of Congress.

Emergency Department Visits Due to Misuse of ADHD Medications Tripled in Five Years

A new study released by the Substance Abuse and Mental Health Services Administration (SAMHSA) shows that emergency department visits due to misuse of attention deficit hyperactivity disorder (ADHD) medications tripled from 5,212 in 2005 to 15,585 in 2010. In 2010, 50% of emergency department visits related to ADHD medications were due to non-medical use of the drug, according to the study. A SAMHSA news release indicates further that in 2010 there were 2.3 million emergency department visits related to the misuse of all drugs. SAMHSA Administrator Pamela S. Hyde stated that "ADHD medications, when properly prescribed and used, can be of enormous benefit to those suffering from ADHD, but like any other medication they can pose serious risks - particularly when they are misused." Hyde explains that these study results show the need to raise awareness among "all segments of society - not just the young - that misuse of these medications is extremely dangerous."

CDC Releases Statistics Showing an Increase in Prescription Drug-Related Deaths for the Eleventh Consecutive Year

The Centers for Disease Control and Prevention (CDC) reported in February that drug overdose deaths increased for the 11th consecutive year in 2010. According to the study, 22,134 deaths involved prescription medications. Opioids were involved in 75 percent of those deaths (16,651). Among the 16,651 overdose deaths involving opioids, 29 percent (4,903) of such deaths involved the use of opioids alone. The rest of the opioid-related deaths involved a combination of opioids and alcohol, other prescription medications, or illicit drugs.

Final Rule Issued Amending Buprenorphine Dispensing Requirements

The U.S. Health and Human Services Department implemented a rule that modifies the dispensing of buprenorphine by opioid treatment programs (OTPs). Prior to the new rule, OTP patients could not take buprenorphine medications home until they had been in treatment for one year. This rule removes the length of time criteria, providing greater flexibility to opioid treatment programs in dispensing take-home supplies of buprenorphine. It is

believed that this new rule will positively impact patients' adherence to treatment.

We hope you enjoyed this latest edition of NASCSA News. We strongly encourage members and others to share information from their respective agencies for consideration for our newsletter. Please email KathyKeough@nascsa.org with your articles and ideas.

Sincerely,

Kathy Keough
Executive Director

NASCSA | 72 Brook Street | Quincy | MA | 02170